ACTU · Insider Trading
Actuate Therapeutics, Inc. Common stock
Every open-market purchase and sale reported by ACTU officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Daniel M Schmitt | President, CEO and Director | MIXED | +151,535 | −$121.73K |
| 2026-05-22 | Amy L Ronneberg | Director | A | +15,000 deriv. | — |
| 2026-05-22 | Todd S Thomson | Director | A | +15,000 deriv. | — |
| 2026-05-22 | Dan Zabrowski | Director | A | +15,000 deriv. | — |
| 2026-05-22 | Roger Sawhney | Director | A | +15,000 deriv. | — |
| 2026-05-22 | Jason A Keyes | Director | A | +15,000 deriv. | — |
| 2026-05-22 | Martin H. Huber Jr. | Director | A | +15,000 deriv. | — |
| 2026-05-22 | Aaron G.L. Fletcher | Director | A | +15,000 deriv. | — |
| 2026-04-01 | Andrew Paul Mazar | Chief Operating Officer | A | +105,000 deriv. | — |
| 2026-04-01 | Daniel M Schmitt | President, CEO and Director | A | +237,000 deriv. | — |
| 2026-04-01 | Paul J Lytle | Chief Financial Officer | A | +105,000 deriv. | — |
| 2026-02-13 | Daniel M Schmitt | President, CEO and Director | MIXED | +150,181 | −$527.71K |
| 2026-01-07 | Kairos Venture Partners II, L.P. | Director | Sell | −560,000 | −$3.25M |
| 2025-06-30 | Aaron G.L. Fletcher | Director | Buy | +714,280 | +$5.00M |
| 2025-06-30 | Bios Equity COF, LP | Director | Buy | +285,712 | +$2.00M |
| 2025-06-30 | Bios Equity Partners II, LP | Director | Buy | +714,280 | +$5.00M |
| 2025-05-23 | Todd S Thomson | Director | A | +15,000 deriv. | — |
| 2025-05-23 | Dan Zabrowski | Director | A | +15,000 deriv. | — |
| 2025-05-23 | Aaron G.L. Fletcher | Director | A | +15,000 deriv. | — |
| 2025-05-23 | Roger Sawhney | Director | A | +15,000 deriv. | — |
| 2025-05-23 | Jason A Keyes | Director | A | +15,000 deriv. | — |
| 2025-05-23 | Amy L Ronneberg | Director | A | +15,000 deriv. | — |
| 2025-04-02 | Daniel M Schmitt | President, CEO and Director | A | +270,788 deriv. | — |
| 2025-04-02 | Paul J Lytle | Chief Financial Officer | A | +91,293 deriv. | — |
| 2025-04-02 | Andrew Paul Mazar | Chief Operating Officer | A | +161,392 deriv. | — |
| 2024-08-20 | BIOS Capital Management, LP | Director | Sell | −249,990 | −$2.00M |
| 2024-08-20 | BP Directors, LP | Director | Sell | −74,997 | −$599.98K |
| 2024-08-20 | Bios Equity Partners II, LP | Director | Sell | −249,990 | −$2.00M |
| 2024-08-16 | Todd S Thomson | Director | MIXED | +12,935,130 | +$26 |
| 2024-08-14 | Paul J Lytle | Chief Financial Officer | A | +234,971 deriv. | — |
| 2024-08-14 | Jason A Keyes | Director | A | +30,000 deriv. | — |
| 2024-08-14 | Roger Sawhney | Director | A | +30,000 deriv. | — |
| 2024-08-14 | Dan Zabrowski | Director | A | +15,000 deriv. | — |
| 2024-08-14 | Amy L Ronneberg | Director | A | +30,000 deriv. | — |
| 2024-08-14 | BP Directors, LP | Director | — | — | — |
| 2024-08-14 | Daniel M Schmitt | President, CEO and Director | A | +544,111 deriv. | — |
| 2024-08-14 | BIOS Fund II, LP | Director | — | — | — |
| 2024-08-14 | BP Directors, LP | Director | MIXED | +29,680,953 | +$11.93M |
| 2024-08-14 | BIOS Advisors GP, LLC | Director | — | — | — |
| 2024-08-14 | Cavu Management, LP | Director | MIXED | +98,936,510 | +$39.75M |
| 2024-08-14 | BIOS Actuate Co-Invest II, LP | Director | MIXED | +98,936,510 | +$39.75M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Todd S Thomson | Director | 1,184,795 | $625.45K |
| Kairos Venture Partners II, L.P. | Director | 873,033 | $460.87K |
| Daniel M Schmitt | President, CEO and Director | 323,939 | $171.01K |
| Bios Equity COF, LP | Director | 307,538 | $162.35K |
| Bios Equity Partners II, LP | Director | 69,375 | $36.62K |
| Aaron G.L. Fletcher | Director | 60,973 | $32.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACTU quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.